Your browser doesn't support javascript.
loading
Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann, Ana Elisa; Soldera, Sara V; Pimentel, Isabel; Ribnikar, Domen; Ennis, Marguerite; Amir, Eitan; Goodwin, Pamela J.
Afiliação
  • Lohmann AE; Department of Oncology, University of Western Ontario, ON, Canada.
  • Soldera SV; Department of Hematology and Oncology, CISSS Montérégie Centre/Hôpital Charles-Lemoyne, Centre Affilié de l'Université de Sherbrooke, QC, Canada.
  • Pimentel I; Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Ribnikar D; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  • Ennis M; Applied Statistician, Markham, ON, Canada.
  • Amir E; Institute of Health Policy Management and Evaluation, University of Toronto, ON, Canada.
  • Goodwin PJ; Division of Medical Oncology and Hematology, Department of Medicine University of Toronto, Princess Margaret Cancer Centre, University Health Network, ON, Canada.
J Natl Cancer Inst ; 113(11): 1465-1475, 2021 11 02.
Article em En | MEDLINE | ID: mdl-33620467
ABSTRACT

BACKGROUND:

Obesity at breast cancer (BC) diagnosis has been associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. We report on the association of obesity or overweight at diagnosis of nonmetastatic BC with disease-free (DFS) and overall survival (OS) in the following defined subtypes hormone receptor positive/HER2 negative (HR+HER2-), HER2 positive (HER2+), and triple negative (TNBC).

METHODS:

We searched MEDLINE, EMBASE, and COCHRANE databases up to January 1, 2019. Study eligibility was performed independently by 2 authors. Studies reporting hazard ratios (HRs) of OS and/or DFS for obesity or overweight in BC subtypes were included. The pooled hazard ratio was computed and weighted using generic inverse variance and random effects models.

RESULTS:

Twenty-seven studies were included. Obese compared with nonobese women had worse DFS in all subtypes the hazard ratios were 1.26 (95% confidence interval [CI] = 1.13 to 1.41, P < .001) for HR+HER2- BC, 1.16 (95% CI = 1.06 to 1.26, P < .001) for HER2+ BC, and 1.17 (95% CI = 1.06 to 1.29, P = .001) for TNBC. OS was also worse in obese vs nonobese women (HR+HER2- BC HR = 1.39, 95% CI = 1.20 to 1.62, P < .001; HER2+ BC HR = 1.18, 95% CI = 1.05 to 1.33, P = .006; and TNBC HR = 1.32, 95% CI = 1.13 to 1.53, P < .001). As opposed to obesity, overweight was not associated with either DFS or OS in HER2+ BC (HR = 1.02, 95% CI = 0.81 to 1.28, P = .85; and HR = 0.96, 95% CI = 0.76 to 1.21, P = .99, respectively) or TNBC (HR = 1.04, 95% CI = 0.93 to 1.18, P = .49; and HR = 1.08, 95% CI = 0.81 to 1.44, P = .17), respectively. In HR+HER2- BC, being overweight was associated with worse OS (HR = 1.14, 95% CI = 1.07 to 1.22, P < .001).

CONCLUSIONS:

Obesity was associated with modestly worse DFS and OS in all BC subtypes.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá